The fact that CCR9 mediates effector T-cell infiltration into the CNS suggests that CCL25/CCR9 is a potential new biologic target for the inhibiting of pathologic lymphocyte recruitment in MS therapy [55]. This evidence concerns the gene CCR9 and myeloid sarcoma.